RxDoctor Payments Data

Ifeoluwa Aderinto

Family · Burbank, CANPI 1578042214

Payments from drug & device makers

$4,412in general payments, 2019–2025

Across 98 payments — averaging $45.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nevro Corp.$3K
  • Abbott$472
  • Boston Scientific$290
  • Vertos Medical, Inc.$140
  • Tersera Therapeutics LLC$97
  • Saluda Medical Americas, Inc.$97
  • plus $556 from 16 others

What the payments were for

  • Travel & lodging$71016%
  • Food & beverage$3,70284%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,412 in reported general payments places this provider in the 90th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$125,488
Medicare patients
567
Services billed
1,771

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Levorphanol Tartrate11$15,344
Fentanyl27$11,511
Diclofenac Sodium60$8,663
Gabapentin412$6,923
Buprenorphine18$2,626
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen204$2,491
Lidocaine17$1,503
Baclofen149$1,303
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen88$1,253
Duloxetine Hcl72$1,209
Pregabalin103$1,123
Cyclobenzaprine Hcl98$863
Acetaminophen-CodeineAcetaminophen With Codeine51$842
Celecoxib21$731
Methadone Hcl42$654

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Virtus Pharmaceuticals LLCLevorphanol Tartrate$19$15,34411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,634 family providers in California.

Other family in Burbank

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →